Open Access Open Access  Restricted Access Subscription or Fee Access

An Overview on Resistant Hypertension: Pathophysiology, Diagnosis, and Management

Asad Jamal Ansari, Nishat Fatima

Abstract


Hypertension is a universal health issue, which is an utmost attributor for the weight of cardiovascular diseases when BP leftovers resistant or stubborn to therapeutic events. Notwithstanding the progressive growth in the antihypertensive therapy, the incidence of resistant hypertension is assessed to be less than 5% of the hypertensive inhabitants. Resistant hypertension is well-defined as blood pressure that leftovers over head the goal line in meanness of the simultaneous usage of 3 antihypertensive drugs of dissimilar classes. It upsurges the risk of stroke, myocardial infarction, congestive heart failure, retinal hemorrhage and renal failure. Resistant hypertension is continuously multifactorial in etiology. Pseudo resistance comprises poor medication observance or white coat hypertension. Secondary reasons of hypertension are common with resistant hypertension which comprises disruptive sleep apnea syndrome, pheochromocytoma, primary aldosteronism, renal parenchymal disease, Cushing’s syndrome, renal artery stenosis and diabetes. Management of resistant hypertension is revised in this article counting pharmacologic treatments, non-pharmacological treatment and devised-based treatment for resistant hypertension. Normally, this review faiths to distribute consultants through a cohesive method for the diagnosis and treatment of resistant hypertension.

Keywords


Device-based management, resistant hypertension, non-pharmacological management, pharmacological management

Full Text:

PDF

References


Saklayen MG, Deshpande NV. Timeline of history of hypertension treatment. Front Cardiovasc Med. 2016; 3: 3.

Persson G, Ekwall B, Fürst C. A clinical trial of Guanoxan (Envacar®) in hypertension resistant to common drugs. Acta Medica Scandinavica. Jan 1967; 182(5): 567−574.

Dargie HJ, Dollery CT, Daniel J. Labetalol in resistant hypertension. British Journal of Clinical Pharmacology. Aug. 1976; 3(4 Suppl 3): 751−755.

Pierdomenico SD, Lapenna D, Bucci A, Tommaso RD, Mascio RD, Manente BM, Caldarella MP, Neri M, Cuccurullo F, Mezzetti A. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. American Journal of Hypertension. Nov 2005;18(11): 1422−1428.

Fagard RH, Cornelissen VA. Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis. J Hypertens. 2007 Nov; 25(11): 2193−2198.

Fatemi O, Goa C, Faselis C, Kokkinos P, Papademetriou V. Improvement in all-cause mortality with blood pressure control in a group of US veterans with drug-resistant hypertension. The Journal of Clinical Hypertension. 2016 Jan; 18(1): 33−39.

Pedrosa RP, Drager LF, Gonzaga CC, Sousa MG, de Paula LK, Amaro AC, Amodeo C, Bortolotto LA, Krieger EM, Bradley TD, Lorenzi-Filho G. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011 Nov; 58(5): 811−817.

de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011 May; 57(5): 898−902.

Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O'Connor PJ, Selby JV, Ho PM. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012 Apr 3; 125(13): 1635−1642.

Dahmardeh H, Sedaghat M. Epidemiological investigation of cardiovascular diseases in Khatamol Anbia Hospital in Zahedan City. Pharmacophores. 2017; 8(6): 60−63.

Ghamri KA, Ghamri RA, Ebtisam AA. Knowledge of cardiovascular risk factors among medical students at King Abdulaziz University. Journal of Advanced Pharmacy Education & Research. 2017; 7(4): 524−530.

Seravalle G, Grassi G. Sympathetic nervous system, hypertension, obesity and metabolic syndrome. High Blood Pressure & Cardiovascular Prevention. 2016 Sep; 23(3): 175−179.

Taltia A, Roy A. Orlistat-an anti-obesity drug: an overview. Journal of Advanced Pharmacy Education & Research. Jul-Sep. 2017; 7(3): 190−193.

Saeed S, Islahudin F, Makmor-Bakry M, Redzuan AM. The practice of complementary and alternative medicine among chronic kidney disease patients. Journal of Advanced Pharmacy Education & Research. Jul-Sep. 2018; 8(3): 30−36.

Smith SM. Epidemiology, prognosis, and treatment of resistant hypertension. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2013 Oct; 33(10): 1071−1086.

Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011 Jun; 57(6): 1076−1080.

Maliha G, Townsend RR. An update on treatment options for drug resistant hypertension. Current Cardiovascular Risk Reports. 2014 Aug 1; 8(8): 394.

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Journal of the American College of Cardiology. 2018 May 15; 71(19): e127−e248.

Hans S, Reilly JP. Resistant hypertension in 2017. Current Opinion in Cardiology. 2017 Jul; 32(4): 389−396.

Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B. Resistant hypertension. BMJ. 2012 Nov 20; 345: e7473.

Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988−2000. JAMA. 2003 Jul; 290(2): 199−206.

Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation. 2012 Apr; 125(13): 1594–1596.

Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011 Aug 30; 124(9): 1046−1058.

Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension. 2011 Jun; 57(6): 1076−1080.

Diaz KM, Booth III JN, Calhoun DA, Irvin MR, Howard G, Safford MM, Muntner P, Shimbo D. Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: The reasons for geographic and racial differences in stroke study. Hypertension. 2014 Sep; 64(3): 465−471.

Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutiérrez OM, Irvin MR, Lackland DT, Oparil S, Warnock D, Muntner P. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clinical Journal of the American Society of Nephrology. 2013 Sep 6; 8(9): 1583−1590.

Borghi C, Tubach F, De Backer G, Dallongeville J, Guallar E, Medina J, Perk J, Roy C, Banegas JR, Rodriguez-Artalejo F, Halcox JP. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. International Journal of Cardiology. 2016 Sep 1; 218: 83−88.

29.Thomas G, Xie D, Chen HY, Anderson AH, Appel LJ, Bodana S, Brecklin CS, Drawz P, Flack JM, Miller III ER, Steigerwalt SP. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the chronic renal insufficiency cohort study. Hypertension. 2016 Feb; 67(2): 387−396.

28.Egan BM, Zhao Y, Li J, Brzezinski WA, Todoran TM, Brook RD, Calhoun DA. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013 Oct; 62(4): 691−697.

Muntner P, Davis BR, Cushman WC, Bangalore S, Calhoun DA, Pressel SL, Black HR, Kostis JB, Probstfield JL, Whelton PK, Rahman M. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension. 2014 Nov; 64(5): 1012−1021.

Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlöf B, Poulter NR, ASCOT investigators. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. Journal of Hypertension. 2011 Oct 1; 29(10): 2004−2013.

Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, O’Connor PJ, Selby JV, Ho PM. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012 Apr 3; 125(13): 1635−1642.

Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. New England Journal of Medicine. 2008 Dec 4; 359(23): 2417−2428.

Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Kjeldsen SE, Cushman W. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood pressure. 2007 Jan 1; 16(2): 80−86.

Smith SM, Huo T, Delia Johnson B, Bittner V, Kelsey SF, Vido Thompson D, Noel Bairey Merz C, Pepine CJ, Cooper-DeHoff RM. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE study. Journal of the American Heart Association. 2014 Feb 28; 3(1): e000660.

Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001 Feb 23; 104(4): 545−556.

Guyton AC, Coleman TG. Long-term regulation of the circulation: interrelationships with body fluid volumes. Physical Bases of Circulatory Transport: Regulation and Exchange. 1967;179.

Guyton AC. Renal function curve—a key to understanding the pathogenesis of hypertension. Hypertension. 1987 Jul; 10(1): 1−6.

Kimura GE, Saito FU, Kojima SH, Yoshimi HI, Abe HI, Kawano YU, Yoshida KA, Ashida TE, Kawamura MI, Kuramochi MO. Renal function curve in patients with secondary forms of hypertension. Hypertension. 1987 Jul; 10(1): 11−15.

Curtis JJ, Luke RG, Dustan HP, Kashgarian M, Whelchel JD, Jones P, Diethelm AG. Remission of essential hypertension after renal transplantation. New England Journal of Medicine. 1983 Oct 27; 309(17): 1009−1015.

Rettig R, Grisk O. The kidney as a determinant of genetic hypertension: evidence from renal transplantation studies. Hypertension. 2005 Sep 1; 46(3): 463−468.

Crowley SD, Gurley SB, Oliverio MI, Pazmino AK, Griffiths R, Flannery PJ, Spurney RF, Kim HS, Smithies O, Le TH, Coffman TM. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. The Journal of Clinical Investigation. 2005 Apr 1; 115(4): 1092−1093.

Coffman TM, Crowley SD. Kidney in hypertension: guyton redux. Hypertension. 2008 Apr 1; 51(4): 811−816.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008 Jun 1; 51(6): 1403−1419.

46.Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002 Dec 1; 40(6): 892−896.

45.Jain G, Ong S, Warnock DG. Genetic disorders of potassium homeostasis. Seminars in Nephrology. 2013 May 1; 33(3): 300−309.

Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. Journal of Hypertension. 2004 Nov 1; 22(11): 2217−2226.

Wei FF, Zhang ZY, Huang QF, Staessen JA. Diagnosis and management of resistant hypertension: state of the art. Nature Reviews Nephrology. 2018 Jul; 14(7): 428−441.

Judd E, Calhoun DA. Apparent and true resistant hypertension: definition, prevalence and outcomes. Journal of Human Hypertension. 2014 Aug; 28(8): 463−468.

Burnier M. Resistant hypertension: Is the number of drugs a reliable marker of resistance. Hypertension. 2016 Dec; 68(6): 1346−1348.

Hannah-Shmouni F, Melcescu E, Koch CA. Testing for Endocrine Hypertension. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–2016 Dec 30.

Spence JD, Sibbald WJ, Cape RD. Pseudohypertension in the elderly. Clinical Science and Molecular Medicine. 1978 Dec; 55(s4): 399s−402s.

Pescatello LS, MacDonald HV, Lamberti L, Johnson BT. Exercise for hypertension: a prescription update integrating existing recommendations with emerging research. Current Hypertension Reports. 2015 Nov; 17(11): 1−10.

Zhang X, Li Y, Del Gobbo LC, Rosanoff A, Wang J, Zhang W, Song Y. Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials. Hypertension. 2016 Aug; 68(2): 324−333.

Dimeo F, Pagonas N, Seibert F, Arndt R, Zidek W, Westhoff TH. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension. 2012 Sep; 60(3): 653−658.

Guimaraes GV, Cruz LG, Tavares AC, Dorea EL, Fernandes-Silva MM, Bocchi EA. Effects of short-term heated water-based exercise training on systemic blood pressure in patients with resistant hypertension: a pilot study. Blood Pressure Monitoring. 2013 Dec 1; 18(6): 342−345.

Dempsey PC, Sacre JW, Larsen RN, Straznicky NE, Sethi P, Cohen ND, Cerin E, Lambert GW, Owen N, Kingwell BA, Dunstan DW. Interrupting prolonged sitting with brief bouts of light walking or simple resistance activities reduces resting blood pressure and plasma noradrenaline in type 2 diabetes. Journal of Hypertension. 2016 Dec 1; 34(12): 2376−2382.

Dempsey PC, Larsen RN, Sethi P, Sacre JW, Straznicky NE, Cohen ND, Cerin E, Lambert GW, Owen N, Kingwell BA, Dunstan DW. Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities. Diabetes Care. 2016 Jun 1; 39(6): 964−972.

Avery L, Flynn D, Van Wersch A, Sniehotta FF, Trenell MI. Changing physical activity behavior in type 2 diabetes: a systematic review and meta-analysis of behavioral interventions. Diabetes Care. 2012 Dec 1; 35(12): 2681−2689.

Larsen RN, Kingwell BA, Sethi P, Cerin E, Owen N, Dunstan DW. Breaking up prolonged sitting reduces resting blood pressure in overweight/obese adults. Nutr Metab Cardiovasc Dis. 2014; 24(9): 976−982.

Pescatello LS, Murphy D, Costanzo D. Low-intensity physical activity benefits blood lipids and lipoproteins in older adults living at home. Age and Ageing. 2000 Sep 1; 29(5): 433−439.

Redfearn DP, Trim GM, Skanes AC, Petrellis B, Krahn AD, Yee R, Klein GJ. Esophageal temperature monitoring during radiofrequency ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology. 2005 Jun; 16(6): 589−593.

Mente A, O’Donnell M, Rangarajan S, Dagenais G, Lear S, McQueen M, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Li W. Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies. The Lancet. 2016 Jul 30; 388(10043): 465−475.

Landstrom AP, Dobrev D, Wehrens XH. Calcium signaling and cardiac arrhythmias. Circulation Research. 2017 Jun 9; 120(12): 1969−1993.

Whelton PK, Appel LJ, Sacco RL, Anderson CA, Antman EM, Campbell N, Dunbar SB, Frohlich ED, Hall JE, Jessup M, Labarthe DR. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation. 2012 Dec 11; 126(24): 2880−2889.

Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell'Italia LJ, Calhoun DA. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009 Sep 1; 54(3): 475−481.

McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, Campbell KL. A randomized trial of dietary sodium restriction in CKD. Journal of the American Society of Nephrology. 2013 Dec 1; 24(12): 2096−2103.

Semlitsch T, Jeitler K, Berghold A, Horvath K, Posch N, Poggenburg S, Siebenhofer A. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev. 2016 Mar 2; 3(3): CD008274.

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Journal of the American College of Cardiology. 2018 May 15; 71(19): e127−e248.

Redfearn DP, Trim GM, Skanes AC, Petrellis B, Krahn AD, Yee R, Klein GJ. Esophageal temperature monitoring during radiofrequency ablation of atrial fibrillation. Journal of Cardiovascular Electrophysiology. 2005 Jun; 16(6): 589−593.

McFadden CB, Brensinger CM, Berlin JA, Townsend RR. Systematic review of the effect of daily alcohol intake on blood pressure. American Journal of Hypertension. 2005 Feb 1; 18(2): 276−286.

Chen L, Smith GD, Harbord RM, Lewis SJ. Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Med. 2008 Mar 4; 5(3): e52.

Briasoulis A, Agarwal V, Messerli FH. Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis. The Journal of Clinical Hypertension. 2012 Nov; 14(11): 792−798.

Husain K, Ansari RA, Ferder L. Alcohol-induced hypertension: Mechanism and prevention. World Journal of Cardiology. 2014 May 26; 6(5): 245−252.

Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Nonas CA. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology. 2014 Jul 1; 63(25 Part B): 2960−2984.

Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension—its identification and epidemiology. Nature Reviews Nephrology. 2013 Jan; 9(1): 51−58.

Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension. 2002 May 1; 39(5): 982−988.

Townsend RR, DiPette DJ, Goodman R, Blumfield D, Cronin R, Gradman A, Katz LA, McCarthy EP, Sopko G. Combined α/βblockade versus β1-selective blockade in essential hypertension in black and white patients. Clinical Pharmacology & Therapeutics. 1990 Dec; 48(6): 665−675.

Saseen JJ, Carter BL, Brown TE, Elliott WJ, Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension. 1996 Jul; 28(1): 109−114.

Stergiou GS, Skeva II, Baibas NM, Roussias LG, Kalkana CB, Achimastos AD, Mountokalakis TD. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. Journal of Cardiovascular Pharmacology. 2000 Jun 1; 35(6): 937−941.

Ouzan J, Pérault C, Lincoff AM, Carré E, Mertes M. The role of spironolactone in the treatment of patients with refractory hypertension. American Journal of Hypertension. 2002 Apr 1; 15(4): 333−339.

Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circulation Research. 2015 Mar 13; 116(6): 1074−1095.

Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. The Lancet. 2012 Aug 11; 380(9841): 591−600.

Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014 Apr 10; 370: 1393−1401.

Briasoulis A, Bakris GL. A clinician’s perspective of the role of renal sympathetic nerves in hypertension. Frontiers in Physiology. 2015 Mar 25; 6: 75.

Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, Ewen S, Tsioufis K, Tousoulis D, Sharp AS, Watkinson AF. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. The Lancet. 2017 Nov 11; 390(10108): 2160−2170.

Kandzari DE, Böhm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, Tsioufis K, Tousoulis D, Choi JW, East C, Brar S. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet. 2018 Jun 9; 391(10137): 2346−2355.

Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, Basile J, Kirtane AJ, Wang Y, Lobo MD, Saxena M. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. The Lancet. 2018 Jun 9; 391(10137): 2335−2345.

Sardar P, Bhatt DL, Kirtane AJ, Kennedy KF, Chatterjee S, Giri J, Soukas PA, White WB, Parikh SA, Aronow HD. Sham-controlled randomized trials of catheter-based renal denervation in patients with hypertension. Journal of the American College of Cardiology. 2019 Apr 9; 73(13): 1633−1642.

Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. Journal of the American College of Cardiology. 2010 Oct 5; 56(15): 1254−1258.

Lobo MD, Sobotka PA, Stanton A, Cockcroft JR, Sulke N, Dolan E, van der Giet M, Hoyer J, Furniss SS, Foran JP, Witkowski A. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. The Lancet. 2015 Apr 25; 385(9978): 1634−1641.

Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018 May 15; 71(19): e127−e248.

Rosa J, Widimský P, Waldauf P, Lambert L, Zelinka T, Táborský M, Branny M, Toušek P, Petrák O, Čurila K, Bednář F. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 study. Hypertension. 2016 Feb; 67(2): 397−403.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Research & Reviews: Journal of Oncology and Hematology